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Structured Summary 
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, and for the first time in 
decades there are new drugs for treatment of this disease.  These new drugs have prompted 
strengthened efforts in DR-TB clinical trials research, and there are now multiple ongoing and 
planned DR-TB clinical trials.  To facilitate comparability and maximize policy impact, a 
common set of core research definitions is needed, and this paper presents a core set of efficacy 
and safety definitions as well as other important considerations in DR-TB clinical trials work.  In 
order to elaborate these definitions, a search of clinical trials registries, published manuscripts, 
and conference proceedings was undertaken to identify groups conducting trials of new regimens 
for the treatment of DR-TB.  Individuals from these groups developed the core set of definitions 
presented here. Further work is needed to validate and assess the utility of these definitions but 
they represent an important first step to ensure there is comparability in MDR-TB clinical trials. 
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Introduction 
Drug-resistant tuberculosis (DR-TB) is a growing public health problem, with more than half a 
million new cases occurring each year1. For the first time in decades, there are several new and 
re-purposed drugs that show potential for improving treatment for persons with all forms of DR-
TB2.  Many of these drugs are being tested in combination regimens through clinical trials that 
are enrolling or planning to enroll participants in the next two years3.  This is the first time there 
has been a core group of researchers, industry partners, policy makers and funders working 
collaboratively on DR-TB clinical trials4.  Because multiple groups will be leading these trials, it 
is important to have a common set of core definitions that are used so that data can be shared and 
compared between the different trials and, ultimately, to generate a more robust evidence-base to 
guide policy.   This paper expands upon regulatory guidance issued in 20135 and proposes core 
research definitions for DR-TB clinical trials in adults that were developed by a group of 
international experts currently involved in DR-TB clinical research.  
Methods 
In order to identify stakeholders, a search of clinical trials registries, published manuscripts, and 
conference proceedings was undertaken to identify groups conducting trials of new regimens for 
the treatment of DR-TB.  A convenience and snowball sampling technique6 was used to identify 
individuals from these groups who were then invited via email to participate in the development 
of the core research definitions.  A total of 31 individuals were identified, of whom 30 agreed to 
participate in the development of the initial core definitions, for a response rate of 96.7% The 
core definitions that emerged from this process were further refined based on feedback provided 
at the Global MDR-TB Clinical Trials Landscape Meeting held by RESIST-TB and The Union’s 
TREAT TB in Washington, D.C., in December 2014.  In some areas, consensus could not be 
reached, and when this occurred options and the rationale for supporting each were documented.   
 
Results 
Proposed Core Research Definitions 
The core definitions for participants with confirmed pulmonary DR-TB considered and discussed 
are presented in Table 1 below.   
Specific  Trial Considerations 
Table 2 reviews detailed comments and suggestions on adapting the core definitions in specific 
clinical trials settings and protocols.   
Additional Components of Trial Design 
  
Table 3 presents recommendations from the group in other areas that are important in the design 
of DR-TB trials. 
 
Discussion 
In this paper, we suggest core research definitions for DR-TB clinical trials that can be used to 
harmonize existing and planned clinical trials. Of note, different trials may need to operationalize 
these definitions in ways that make the most sense for their trial in the context in which it will be 
conducted. For this reason, complete consensus was not always be possible, even between 
closely collaborating research groups; yet the aim in putting forth the recommended definitions 
is  be to strive for the highest achievable level of transparency and data comparability.  Lack of 
strict consensus was also due to differences in objectives and interpretation of existing data and 
genuine uncertainty in the absence of hard data.  Areas in which consensus was not possible 
highlight gaps that could be addressed through future research, including meta-analyses. For 
example, the wide range of acceptable intervals between culture samples used for defining 
culture conversion is not based on hard evidence but rather on prevailing convention and trial 
logistics.  Other areas in which it was difficult to reach consensus and further research is 
warranted in the use of liquid or solid media, the definition of treatment failure, especially when 
there is only one positive culture and clinical improvement, and the specified period of follow-up 
in trials that have arms of different lengths. The definitions we propose are meant to reflect the 
minimum standard that would allow cross-trial comparability.  Indeed, there is flexibility to 
pursue more stringent criteria.  Ultimately, based on further evidence and practical experience 
with implementation and use, revision of these definitions may be needed.   
There were multiple limitations to the approach used.  First, the group of researchers 
participating in this development process was not randomly selected and may not have included 
or be representative of all individuals working on DR-TB clinical trials. Attempts were made to 
be comprehensive in inclusion, but some individuals working on DR-TB trials may have been 
overlooked.  Second, there was almost never complete consensus on the definitions, and it is 
possible that the majority or more active voices may have prevailed in the definitions we 
propose.  Areas of debate are detailed in Table 2.  Including the specifics of these debate in the 
results was felt to be important to illustrate the areas in which there was not complete agreement. 
At the same time the inclusion of a number of dissenting opinions may also weaken the 
recommendations of the core definitions. Finally, these definitions have yet to be validated in 
trials. 
 
Conclusion 
  
A set of core research definitions for DR-TB clinical trials were developed through a systematic 
process and are presented in this paper.  In spite of the limitations mentioned above, it is 
recommended that these definitions be used as a minimum core set in all planned and future DR-
TB trials. Clinical trialists, statisticians, microbiologists, government agencies, pharmaceutical 
companies, government-funded trials networks, and non-governmental organizations that are the 
most heavily engaged in DR-TB trial design, implementation, and analysis were all involved in 
the development of these definitions and thus they represent the current state-of-the-field. 
Ongoing and planned trials can help validate these core definitions and assess their utility. We 
are hopeful that these research definitions will be a useful tool that can help advance DR-TB 
research during this time of renewed interest in and availability of new drugs and potentially 
transformative new combination regimens for participants with this highly-morbid, often-fatal 
communicable disease.   
Table1: Core Definitions 
Measure Proposed Definition 
Sputum culture conversion At least two consecutive negative sputum cultures taken between 7. to 
30 days apart at a trial-defined time point after at least one initial 
positive sputum. One missing or contaminated culture may occur 
between the two negative cultures. Inability to produce sputum even 
with induction is considered to be a negative result.  Sputum culture 
conversion is said to occur at the time of the first negative culture. 
  
 
Favorable outcome A participant’s last two culture results at the end of treatment are 
negative and the participant has not been classified as having an 
unfavorable outcome by a study-defined time point.   
 
 
   
Death Death of a participant from any cause beginning at the time of 
randomization and extending through the specified follow-up period. 
 
 
Treatment failure The presence of a positive mycobacterial culture from at least one 
specimen beginning at a specified month.  
 
 
  
 
 
Lost-to-Follow-up 
 
 
Failure to complete the full duration of follow-up as specified in the 
trial protocol.  
 
.   
  
 
 
 
Recurrence  
 
 
Diagnosis of DR-TB during the pre-defined follow up period after 
previous documentation of successful treatment completion  
 
  
Unfavorable outcome Composite outcome that includes death, treatment failure, treatment 
discontinuation, and recurrence (see comment in Table 2).  
 
 
Treatment 
discontinuation/modification 
Discontinuation or modification of treatment, for any reason, based on 
a decision by the trial participant, trial investigator or trial safety 
monitoring body. 
 
  
Multidrug Background 
Therapy/ Regimen 
(MBT/MBR) 
A regimen that meets local standards for the treatment of DR TB.  
 
 
Adequate adherence Achievement of a targeted level of adherence (e.g. ≥ 90% of 
doses)  within a trial-specified time period. 
 
 
 
 
Unassessable  There is insufficient information for the participant to contribute to the 
assessment of the primary endpoint. 
 
Safety  Proportion of participants experiencing a grade 3 or higher adverse 
event during treatment and follow-up 
 
AND 
 
any lower grade events that result in treatment 
modification/discontinuation 
 
 
 
 
 
Table 2: Specific Trial Considerations 
Variable Considerations for specific trials 
Sputum culture conversion The precise number of days apart must take into account two issues.  The 
number of days apart must be long enough to signify a meaningful biological 
change.  Conventionally, this number is usually 30 days, although a longer 
period of time could be used depending on the trial design.  The number of 
  
days apart must also ensure that the two samples are taken on different days.  
Conventionally, this number is 7 days although the period of time could be as 
short as 1 day. 
Time periods between the cultures will differ depending on the goal of the 
trial. Regulatory agencies have accepted a minimum of 7 days apart in some 
treatment shortening trials7.  Logistical issues faced in trial execution may also 
determine the precise definition in each clinical trial. 
Trials will also need to decide what to do if a participant has one negative 
culture and then dies or if the confirmatory culture at the specified endpoint is 
contaminated or lost.  
Secondary/sensitivity analyses that investigate stricter and more inclusive 
alternate definitions can be important in trial interpretation. 
Future trials with more robust regimens may want to increase the number of 
cultures during the specified time period (i.e. 3 or 4 negative cultures within a 
30 day period).  This may be more important in non-inferiority trials compared 
with superiority trials. 
A maximum time period is given to avoid a situation in which a participant has 
one negative culture and subsequent cultures are assessed at longer intervals 
after longer durations of therapy  to increase the likelihood that those 
subsequent cultures will stay negative 
Favorable outcome Trials could include clinical indicators of favorable outcomes as well, although 
such clinical indicators have not necessarily been shown to correlate with 
microbiologic outcomes8. 
 
 
Death The cause of death should also be determined and reported and might be 
incorporated in secondary/sensitivity analyses 
 
In some trials, all deaths are counted as unfavorable, while in others, certain 
types of deaths (i.e. traumatic deaths, deaths during childbirth) are counted as 
“unassessable”.  
 
Treatment failure The specified month will depend on the trial objectives and the length of the 
regimen being assessed.  In general, this should be in the final third of the 
expected treatment period.  
 
Of note, there is limited evidence that a single positive culture during a trial 
necessarily indicates failure, and it is recommended that clinical considerations 
be taken into account when assessing the significance of a single positive 
culture9.  The trial protocol will need to specify the clinical indicators to be 
assessed.  
 
Trials will need to decide what to do if the cultures are not “positive” but only 
have a few colonies. 
 
  
 
 
Lost-to-Follow-up 
 
 
Classification of these individuals in the analysis will vary depending on the 
trial protocol.  In general, a participant is considered to be lost to follow-up if 
he or she does not contribute data to the primary endpoint. 
 
 
Trials should allow for such participants to contribute data to 
secondary/sensitivity analysis.  For example, if a participant is lost to follow 
up late into the trial but does contribute data to a secondary objective (i.e. 
culture data at 6 months), the participant could be included in the analysis of 6 
month endpoints. 
 
This could also include individuals who withdraw consent, individuals who 
required the use of prohibited medications, or individuals who did not return 
for trial visits. 
 
Another situation to be considered in each trial is how to handle data from 
participants that may be available outside of the trial.  For example, if a 
participant does not come for trial visits but does show up for routine care. 
 
Each trial should detail how they will handle these conditions in the statistical 
analysis plan. 
 
Recurrence  
 
 
This could be due to re-infection in which there is evidence that the recurrence 
is with a different strain of Mycobacterium tuberculosis.  This could also be 
due to relapse for which there is evidence that the recurrence is due to the same 
strain recorded in the baseline specimen.   
 
Some trials consider both to be an unfavorable outcome, although others do 
not consider re-infection to be an unfavorable outcome.  Reinfection is often 
included as an unfavorable outcomes in trials because it may be a censoring 
endpoint and thus the final endpoint may be unassessable. 
 
 
In order to determine if the recurrence is due to relapse or re-infection, 
genotyping analyses of the mycobacterial DNA strain are needed.  Resources 
for doing these analyses should be built into trial budgets whenever possible. 
Unfavorable outcome Although this composite endpoint has been used in many TB clinical trials, 
each of the separate outcomes included in the composite endpoint likely 
represents a qualitatively different outcome which may be obscured when they 
are all grouped together.  For this reason, it is recommended that each of the 
specific endpoints included in the composite outcome be assessed separately. 
 
Trials could include clinical indicators of unfavorable outcomes as well. 
  
Treatment 
discontinuation/modification 
Some potential reasons for this could be protocol-defined toxicity, withdrawal 
of consent, or non-adherence to trial procedures.  
Multidrug Background 
Therapy/ Regimen 
(MBT/MBR) 
Also referred to as “appropriate combination regimen” or “optimized 
backbone regimen”  
 
These standards could include a WHO-recommended regimen, the contents of 
which are consistent with WHO guidelines, or a regimen recommended by 
another recognized national or international expert group. 
 
Adequate adherence More detailed definitions will depend on the goal of the trial and should be 
specified within the trial protocol/manual of operating procedures. 
 
90% was chosen based on a recent study of treatment interruptions that found 
patient who missed more than 10% of doses had worse clinical outcomes10. 
Unassessable  This could be due to a number of reasons, and trial protocols will need to 
specify what the criteria for “unassessble” are and how such participants will 
be handled in the primary and secondary analyses. 
 
In the past, most unassessable participants were classified as unfavorable 
outcomes.  However in TB trials, not all unassessable outcomes may be 
unfavorable11. Determining if an unassessable outcome is unfavorable will 
depend on the trial design and goals of the trial. 
 
Safety  Continued assessment and grading of adverse events during the follow-up 
period is especially important for drugs with a long terminal half- life. 
 
Targeted safety endpoints should include drug-specific concerns, such as QT 
prolongation  
 
Trial protocols will need to specify the grading scales to be used (see point 6 
below). 
 
Causality relatedness should also be assessed following CIOMS guidelines12. 
 
 
Table 3: Unresolved Issues in Clinical Trials 
 
Issue Recommendation Comment 
  
Type of culture media used Both solid and liquid media 
should be used in planned trials, 
but liquid media is becoming the 
more accepted type. 
 
Liquid media is more 
sensitive than solid media for 
culture, especially with 
numbers of bacilli are low or 
if the bacilli have been 
exposed to medications.  
Furthermore, liquid culture 
systems are commercially 
manufactured and widely 
marketed thus providing a 
standardized  product (culture 
media) and 
facilitating harmonization 
(same method and product 
used by all) among the labs 
participating in multi-national 
trials. 
 
Studies have shown different results in solid 
media versus liquid media, and for this 
reason it would be ideal to use both media 
types. 
Length of follow up All participants should be 
followed for the same overall 
period of time, beginning at the 
time of randomization.  
The number of months from randomization 
will depend on the goals of the trial, but the 
period should include a minimum of 6 
months after treatment completion for all 
participants; a maximum of 12 months is 
likely to be sufficient.  A minimum of 6 
months is recommended because a majority 
(80%) of relapses will occur in the first six 
months after treatment has been 
completed13. 
 
Some trials may elect to follow all 
participants for a defined period of time 
AFTER completion of treatment.  Both 
approaches introduce some forms of biases, 
but following from the time of 
randomization seems to favor the control 
regimen and may be more robust in the 
design of non-inferiority trials. 
 
 
  
Role of molecular tests (i.e. 
Xpert MTB/RIF®, Hain 
Lineprobe version 2.0®) 
Acceptable to define eligibility 
for inclusion, provided the result 
is confirmed by a phenotypic 
DST method specified in the 
protocol 
Participants with a positive Xpert 
MTB/RIF® or HAIN MTBdr plus (version 
2.0) but a negative culture be excluded from 
efficacy analyses based on the trial 
endpoints and discretion of the investigator 
and that those positive for DR-TB by a new 
method be confirmed by a standard method. 
 
Predictor variables It is recommended that 
information about variables 
commonly associated with 
response to TB treatment be 
collected. 
Could include:  1) HIV status; 2) CD4 count 
if HIV positive; 3) body mass index; 4) 
presence of diabetes mellitus; 5) anemia; 6) 
extrapulmonary TB; 7) socioeconomic 
status; 8) tobacco use; 9) radiographic 
extent of disease; 10) other concomitant 
immunosuppressing conditions; 11) history 
of liver disease; 12) other concomitant 
infectious diseases such as malaria or other 
parasitic diseases, in endemic settings; and 
13) smear grade 
Monitoring for resistance 
development 
Samples should be stored and 
tested for resistance at baseline 
and over the course of treatment, 
with an emphasis on testing 
samples collected from 
participants with treatment 
failure or relapse. 
This may be especially important for drugs 
that have long terminal half-lives (or that 
have metabolites with long half-lives), 
given that drug may persist in the serum or 
tissues long after therapy is stopped. 
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